Samidorphan (ALKS33; RDC0313; ALKS-33; RDC-0313; Lybalvi) is a novel and potent μ-opioid modulator (antagonist) approved in 2021 by FDA in the form of olanzapine/samidorphan (trade name Lybalvi) for the treatment of schizophrenia and bipolar disorders. Samidorphan acts primarily an antagonist or very weak partial agonist of the μ-opioid receptor (MOR) and to a lesser extent as a partial agonist of the κ-opioid receptor (KOR) and δ-opioid receptor (DOR).

纯度：≥98%

CAS：852626-89-2